Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) had its target price boosted by equities research analysts at Stifel Nicolaus from C$16.00 to C$17.00 in a report released on Wednesday, BayStreet.CA reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 17.32% from the company’s previous close.
A number of other research firms also recently commented on CPH. Stifel Canada upgraded Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th. Leede Financial downgraded Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 13th.
View Our Latest Stock Analysis on CPH
Cipher Pharmaceuticals Price Performance
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last announced its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 EPS for the quarter, beating the consensus estimate of C$0.15 by C$0.01. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. The business had revenue of C$7.26 million for the quarter, compared to the consensus estimate of C$7.52 million. Analysts expect that Cipher Pharmaceuticals will post 1.4156977 earnings per share for the current fiscal year.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Recommended Stories
- Five stocks we like better than Cipher Pharmaceuticals
- What is the Dogs of the Dow Strategy? Overview and Examples
- Analyst Think There’s Still Time to Get in on Edgewise, Up 332%
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Stocks Raising Dividends 4X Higher Than Inflation
- Profitably Trade Stocks at 52-Week Highs
- Palantir Stock Joins the S&P 500; Is It Time to Buy?
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.